natgillin/translations-raw huggingface dataset:
An induction period wherein Cladribine is to be administered and wherein the total dose of Cladribine reached at the end of the induction period is from about 1.7 mg/kg to about 3.5 mg/kg; 
(i) period indukcije pri čemu se primjenjuje Kladribin i pri čemu ukupna doza Kladribina koja je dosegnuta na završetku perioda indukcije je od oko 1.7 mg/kg do oko 3.5 mg/kg;
The formulation of any of items 1 to 10, wherein the excipient is a saccharide, a non-reducing sugar and/or polyol. 
Formulacija prema zahtjevu 8, naznačena time što je pomoćna tvar saharid, nereducirajući šećer i/ili poliol.
Hard gelatine capsules may contain enteric-coated granules of the active compound. 
Kapsule tvrde želatine mogu sadržavati izvana obložene granule aktivnog spoja u kombinaciji
Thus, one embodiment relates to a process for the preparation of the (S, S)— or (R, R)-enantiomer of the compound of formula V (i.e. 
Postupak pripreme spoja formule I ili njegove soli koji obuhvaća reakciju spoja formule Vla (tj.
which is subsequently deprotected and reacted with (R)-(+)-propylene oxide in a suitable solvent, and optionally recrystallized to improve quality, to afford Compound H of the formula which is reacted with a Cbz-L-alanine and a coupling agent to afford Compound J of the formula which is deprotected and crystallized to afford crystalline Compound I. 
€) s kojeg se zatim uklanja zaštita 1 reagira s (R)-(+)-propilen oksidom u odgovarajućem otapalu, i po izboru se Tekristalizira radi poboljšanja kvalitete, a da se dobije Spoj H formule 28) s kojeg se uklanja zaštita i rekristalizira se da se dobije kristalni Spoj I.
the third domain VLB of the first polypeptide chain is in association with the second domain VHB of the second polypeptide chain to form an antigen binding site specific for the tumor cell; and the fourth domain VHA of the first polypeptide chain is in association with the first domain VLA of the second polypeptide chain to form an antigen binding site specific for CD3. 
- treća domena VLB prvog polipeptidnog lanca je povezana s drugim domenom VB drugog polipeptidnog lanca da bi se oblikovalo antigen-vezujuće mjesto specifično za tumorsku stanicu; i - < četvrta domena VrA prvog polipeptidnog lanca je povezana s prvom domenom VLA drugog polipeptidnog lanca da bi se oblikovalo antigen-vezujuće mjesto specifično za CD3.
a step that uses a template developed during a configuration in order to apply an alert method as a parameter of the residual flow rate (Dj) on the basis of a determination that the residual flow rate (Dj) is not in a normal operating zone. 
• korak (12-7) korištenja predloška razvijenog tijekom podešavanja radi određivanja ako zaostali protok Dj nije u uobičajenom radnom području i stoga ako treba započeti postupak upozoravanja (12-8) na temelju zaostalog protoka Dj i u bilo kojem slučaju povratak na korak (12-1).
Compounds of the present invention typically do not cause vasodilation at doses as high as about 300 mpk as measured using methods know in the art, such as the method shown in Example 7. 
Spojevi prikazanog izuma tipično ne uzrokuju vazodilataciju pri dozama visine od oko 300 mpk mjereno uporabom postupaka poznatih u struci, poput postupka prikazanog u Primjeru 7.
the boronic ester compound of formula (I) is: 
(b) spoj ester organoborne kiseline formulo (1) je: ili
Further described in the following lettered paragraphs are (AA) A Compound of Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein 
PATENTNI ZAHTJEVI Spoj formule I: ili njegov pojedinačni stereoizomer ili smjesa stereoizomera i izborno kao njegova farmaceutski prihvatljiva sol ili solvat, gdje
wherein the salt is an inorganic or organic salt, or combination thereof, such as halide, phosphate, phosphite, carbonate, bicarbonate, sulphate, bisulfate, hydroxide, nitrate, persulfate, sulfite, sulphide, acetate, ascorbate, benzoate, citrate, dihydrogen citrate, hydrogen citrate, oxalate, succinate, tartrate, taurocholate, glycocholate, cholate. 
Postupak prema zahtjevu 1, naznačen time da je sol spoja prema formuli (IV) anorganska ili organska sol, odabrana iz skupine koja se sastoji od halida, fosfata, fosfita, karbonata, bikarbonata, sulfata, bisulfata, hidroksida, nitrata, persulfata, sulfita, sulfida, acetata, askorbata, benzoata, citrata, dihidrogen citrata, hidrogen citrata, oksalata, sukcinata, tartrata, taurokolata, glikokolata i kolata.
The method according to any one of items 58-64 wherein the aminooxy linker is selected from the group consisting of: 
Postupak prema bilo kojem od zahtjeva 28-32, pri čemu je aminooksi veznik odabran od skupine koja se sastoji od: a)
The (2' R)-2'-deoxy-2'-fluoro-2'- C -methyl nucleoside (B-D) of claim 1 or its pharmaceutically acceptable salt thereof, R7 is H and R1 is a diphosphate or a triphosphate. 
(2'R)-2'-deoksi-2'-fluoro-2'-C-metil nukleozid (B-D ili B-L) iz patentnog zahtjeva 1 ili njegova farmaceutski prihvatljiva sol, u kojima R7 je H i R1 je monofosfat, difosfat, ili trifosfat.
reacting said purified Compound 8 with a secondary amine and a carboxylic acid in a first solvent to produce Compound 10: 
(d) reakciji navedenog pročišćenog Spoja 8 sekundarnim aminom i karboksilnom kiselinom u prvom otapalu kako bi se dobilo Spoj 10: i
The method of embodiment 30, wherein the donor sequence is introduced to the cell using a viral vector, as an oligonucleotide or on a plasmid. 
(a) donorska sekvenca se uvodi u stanicu upotrebom virusnog vektora, kao oligonukleotid ili u okviru plazmida;
The frozen tablets were then dried by sublimating the ice in a freeze dryer. 
Zamrznute tablete osušene su sublimacijom leda u sušioniku za led.
In accordance with a fifteenth aspect, a transform-based decoder may be configured to decode a transform coefficient block using an apparatus 150 for decoding a significance map indicating positions of significant transform coefficients within the transform coefficient block from a data stream, in accordance with at least one of the first to eleventh aspects, and to perform 152 a transform from spectral domain to spatial domain to the transform coefficient block. 
Dekoder na bazi transformacije, naznačen time, da je konfiguriran za dekodiranje bloka koeficijenata transformacije uporabom uređaja (150) za dekodiranje signifikacijske mape iz protoka podataka, koja prikazuje pozicije sigmifikantnih koeficijenata transformacije unutar bloka koeficijenata transformacije, prema bilo kojem od zahtjeva 1 do 9, te za izvođenje (152) transformacije iz spektralne domene u prostornu domenu u bloku koeficijenata transformacije.
The present invention further provides methods of preparing a salt of the invention comprising combining (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile with maleic acid, sulfuric acid, or phorphoric acid. 
Postupak pripreme soli prema bilo kojem od patentnih zahtjeva od 1 do 5 koji podrazumijeva kombiniranje (R)-3- (4-(7H-pirolo[2,3-dlpirimidin-4-il)-1H-pirazol-1-il)-3-ciklopentilpropan-nitrila sa - maleinskom = kiselinom, sumpornom kiselinom ili fosfornom kiselinom.
The pharmaceutical composition of claim 1, comprising an effective amount of the compound of the structure: wherein the pharmaceutical composition is in the form of a liquid dosage form. 
Farmaceutski sastav koji sadrži učinkovitu količinu spoja prema bilo kojem od patentnih zahtjeva od 1 do 14 ili njegovu farmaceutski prihvatljivu sol.
a gelatin film adhered to the core; or a dried proteinaceous gel. 
proteinski premaz sadrži neprekidni želatinasti film koji prianja uz jezgru;
Composition according to claim 1 comprising the following components, expressed in weight percent concentration: Olive oil 90.30% 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time što sadrži sljedeće komponente, izražene u težinskoj postotnoj koncentraciji: maslinovo ulje 90,30% simetikon USP
A medicament for treatment and/or prophylaxis defined in claim 24, wherein a disease mediated by peroxisome proliferator activated receptor is dyslipidemia, metabolic syndrome, obesity including internal-organs fat type, atherosclerosis or disease associated therewith, or diabetes. 
Spoj ili njegova farmakološki prihvatljiva sol za uporabu prema patentnom zahtjevu 4, gdje je bolest dislipidemija, metabolički sindrom, gojaznost uključujući tip masti unutarnjih organa, ateroskleroza ili bolest povezana s njom, ili dijabetes.
The isolated antibody or antigen binding fragment thereof of claim 13, wherein the antibody does not contain detectable sialic acid residues. 
10. Izolirano antitijelo prema zahtjevu 9, naznačeno time, da antitijelo ne sadržava mjerljive ostatke sijalne kiseline.
A combination according to any one claims 1 to 3, wherein the B2 agonist is selected from the group comprising arformoterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, dopexamine, fenoterol, formoterol, hexoprenaline, ibuterol, isoprenaline, levosalbutamol, mabuterol, meluadrine, nolomirole, orciprenaline, pirbuterol, procaterol, (R,R)-formoterol, reproterol, ritodrine, rimoterol, salbutamol, salmeterol, sibenadet, sulfonterol, terbutaline, tulobuterol, GSK-597901, GSK-159797,KUL-1248,TA-2005 and QAB-149, optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. 
Kombinacija sukladno patentnom zahtjevu 1 III 2, naznačena time, da je P2 agonist odabran iz skupine koja sadrži arformoterol, bambuterol, bitolterol, broksaterol, karbuteroi, clenbuterol, dopeksamin, fenoterol, formoterol, heksoprenalin, ibuterol, izoprenalin, levosalbutamol, mabuterol, meluadrin, nolomirol, orciprenalin, pirbuterol, prokaterol, (R,R)-formoterol, reproterol, ritodrin, rimoterol, salbutamol, salmeterol, sibenadet, sulfonterol, terbutalin, tulobuterol, GSK-597901, GSK-159797, KUL-1248, TA-2005 i OAB-149, opcionalno u obliku njihovih racemata, eneantiomera, diastereomera i njihovih smjesa te opcionalno njihovih farmaceutski kompatibilnih kiselinskih adicijskih soli.
In one embodiment, the Type II anti-CD20 antibodies have been engineered to have an altered pattern of glycosylation in the Fc region. 
(ii) kako bi imalo povećani postotak dvosekcijskih oligosaharida u Fc području u usporedbi prema odgovarajućem protutijelu koje nije bilo podvrgnuto glikoinženjeringu;
The composition according to any one of the preceding claims, wherein the organic solvent has a boiling point of below 100 °C. 
Pripravak za primjenu prema bilo kojem od prethodnih zahtjeva, naznačen time, što organsko otapalo ima vrelište ispod 100 "€, a poželjno ispod 80 *C.
A fused grit having the following chemical composition, in percentages by weight: 
Stopljena sitna zrnca naznačena time da ima sljedeći kemijski sastav, u težinskim postocima:
The composition, separate dosage forms or package according to any of claims 9-15, comprising 10-60 mg of the compound of Formula I or pharmaceutically acceptable salt thereof, and 2.5-30 mg quinidine. 
Smjesa, zasebni dozirni oblici ili pakiranje prema bilo kojem od zahtjeva 7-13, koji sadrže 10-60 mg spoja Formule I ili njegove farmaceutski prihvatljive soli, i 2.5-30 mg kinidina.
2-[2-(2-hydroxyethyl)-1H-indol-6-yl]-5,7-dimethoxy-3H-quinazolin-4-one, and tautomers, stereoisomers, pharmaceutically acceptable salts, and hydrates thereof. A pharmaceutical composition comprising a compound according to items 39 or 40 and a pharmaceutically acceptable carrier. 
2-[4-(3-hidroksi-propil)-3,5-dimetoksifenil]-5,7-dimetoksi-3H-kinazolin-4-on; i 2-[4-(3-hidroksi-propil)-3-metoksi-fenil]-5,7-dimetoksi-3H-kinazolin-4-on; i njihovi tautomeri, stereoizomeri, njihove farmaceutski prihvatljive soli, ili njihovi hidrati.
reacting compound (12), or salt thereof, with an activated (e.g. metallated) biphenylic compound to obtain a compound according to formula (13), or salt thereof, 
b) reakcija spoja prema formuli (12) ili njegove soli, s aktiviranim (naime metaliranim) bifenilnim spojem, kako bi se dobio spoj u skladu sa sljedećom formulom (13) ili njegova sol: gdje RI je vodikova ili dušikova zaštitna skupina, i
wherein R and R′ taken together with the nitrogen atom they are linked to represent a protected primary amino group, with 4-hydroxy-3-methoxyacetophenone of formula (VII): 
s (VD u kojem R i R* zajedno s dušikovim atomom za koji su vezani predstavljaju zaštićenu amino-skupinu, sa spojem formule (XVI):
A method of preparing a pharmaceutical composition, said method comprising admixing a GPR119 agonist and a DPP-IV inhibitor, together with at least one pharmaceutically acceptable carrier. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da pripravak je farmaceutski pripravak koji sadrži GPR119 agonist i DPP-IV inhibitor skupa s barem jednom farmaceutski prihvatljivom podlogom.
a unit (16) for controlling and coordinating the operations performed in said stations (10, 32, 40, 54, 60), 
jedinicu (16), za upravljanje i koordiniranje operacijama koje se provodi u navedenim postajama (10, 32, naznačen time što:
Conduit 52 can be of the same or similar material as conduit 14. 
Cjevovod 52 može biti od istog ili sličnog materijala kao i cjevovod 14.
The method according to claim 29, wherein the oxidizing agent is cumene hydroperoxide. 
Postupak prema zahtjevu 23, naznačen time da oksidacijsko sredstvo je kumen hidroperoksid.
The figure shows the holding member 28, which is movable as shown by arrow 36. 
Slika prikazuje član za držanje 28, koji se može pomicati na način kako je prikazano strelicom 36.
The compound for use according to claim 8, characterized in that Ar represents a group selected from the following groups: 
Spoj za upotrebu prema patentnom zahtjevu 7, naznačen time da Ar predstavlja skupinu odabranu od sljedećih skupina: [image]
The floor panels as claimed in claim 1, wherein the vertical flexing grooves are covered with an underlay. 
Podne ploče na bazi vinila prema patentnom zahtjevu 1, naznačene time što su okomito savitljivi žljebovi prekriveni s podlogom (18).
The veterinary or agricultural composition of claim 22, wherein the cyclic depsipeptide is emodepside. 
Veterinarski ili agrikulturni sastav prema zahtjevu 22, naznačen time, da ciklički depsipeptid je emodepsid.
transmitting the signal frame via a signal, 
Neodulacija okvira signala ž i
Use of a compound: for preparing copanlisib (10): or copanlisib dihydrochloride (11): or copanlisib dihydrochloride hydrate I, or copanlisib dihydrochloride hydrate II. 
Uporaba spoja: za pripravu kopanlisiba (10): ili kopanlisib dihidroklorida (11): ili kopanlisib dihidroklorid hidrata I, ili kopanlisib dihidroklorid hidrata II.
Compounds according to claims 1 or 2 selected from: 
Spojevi prema zahtjevu 1 ili 2, naznačeni time, da su izabrani iz skupine koju čine:
The method of claim 1, wherein said transthyretin amyloid disease is selected from the group consisting of familial amyloid polyneuropathy, familial amyloid cardiomyopathy, senile systemic amyloidosis, central amyloidosis, ocular amyloidosis, Leptomeningeal amyloidsis, oculoleptomengial amyloidosis, vitreous amyloidosis, gastrointestinal amyloidosis, neuropathic amyloidosis, non-neuropathic amyloidosis, non-hereditary amyloidosis, reactive/secondary amyloidosis, cerebral amyloidosis. 
Spoj prema bilo kojem od zahtjeva 1 do 5, ili sastav prema zahtjevu 6, naznačen time, da se upotrebljava u liječenju porodične amiloidne polineuropatije, porodične amiloidne kardiomiopatije, leptomeningne amiloidoze, senilne sustavne amiloidoze, centralne amiloidoze, okularne amiloidoze, amiloidoze staklovine, ili CNS amiloidoze.
As shown in FIGS. 1, 2 and 3, incliningly extending web parts 26, 27, 26 ′, 26 ″, which can serve for the affixation of the mentioned bearing holders 12, 22, and 12 ′, 12 ″ respectively, may be provided on the intermediate rail 10, 10 ′ and 10 ″ in relation to the intermediate rail 10 and 10 ′, 10 ″. 
Mehanizam za izvlačenje ladice u skladu s jednim ili s više patentnih zahtjeva 1 do 3, naznačen time što su predviđeni na pojedinim mjestima na među-tračnici (10; 10; 107) dijelovi staze koji se prostiru pod nagibom (26, 26, 26") 1 koji mogu služiti za učvršćenje držača ležaja (12, 22; 12%; 12%) u odnosu na među-tračnicu (10; 10%; 107).
The prostate therapy system of any one of claims 12 or 13, wherein at least part of the introducer (102) and at least part of the ablation probe (120) have complementary shapes preventing rotation of the ablation probe (120) with respect to the introducer (102). 
Sustav prema zahtjevu 1, naznačen time da barem dio uvodnika (102) i barem dio sonde za ablaciju (120) imaju komplementarne oblike koji sprječavaju rotaciju sonde za ablaciju u odnosu na uvodnik.
a nucleoside reverse transcriptase inhibitor; and 
inhibitor nukleozidne reverzne transkriptaze; i
The compound, the pharmaceutically acceptable salt, or the solvate thereof, for use in treating and/or preventing influenza infectious disease according to claim 1, wherein R1 is hydrogen, halogen, hydroxy, carboxy, lower alkyl optionally substituted by substituent group A, lower alkenyl optionally substituted by substituent group A, lower alkyloxy optionally substituted by substituent group A, lower alkyl carbonyl optionally substituted by substituent group A, lower alkyloxycarbonyl optionally substituted by substituent group A, heterocyclic group optionally substituted by substituent group A, or 
Spoj, njegova farmaceutski prihvatljiva sol, ili njegov solvat, za uporabu u liječenju i/ili prevenciji infektivne bolesti gripe prema zahtjevu 1, naznačen time, da R' je vodik, halogen, hidroksi, karboksi, niži alkil prema potrebi supstituiran sa supstituentskom skupinom A, niži alkenil prema potrebi supstituiran sa supstituentskom skupinom A, niži alkiloksi prema potrebi supstituiran sa supstituentskom skupinom A, niži alkilkarbonil prema potrebi supstituiran sa supstituentskom skupinom A, niži alkiloksikarbonil prema potrebi supstituiran sa supstituentskom skupinom A, heterociklička skupina prema potrebi supstituirana sa supstituentskom skupinom A,ili
A control system for anti-roll stabilization of watercraft standing at anchor, comprising: 
Kontrolni sustav za stabilizaciju protiv okretanja plovila (202) koje stoji usidreno, naznačen time da sadrži:
generate transformation coefficients based on the predictor and the image, and generate a bitstream including the information about the maximum size of the coding unit, the information about coding units, the information about the prediction unit, the information about the transformation unit and the transformation coefficients, 
Postupak dekodiranja slike, te postupak sadrži: dobivanje kvantificiranih koeficijenata transformacije za transformacijsku jedinicu u jedinici za kodiranje provođenjem entropijskog dekodiranja na kodiranom toku bitova na temelju jedinice kodiranja;
The tapping fitting according to claim 1, wherein the clamping lever is formed in two parts, with a basis part, which has the sliding profile and which is connected to the clamping band, and with a lever and gripping part, which is connected to the basis part by means of a removable connection. 
Armatura za bušenje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je poluga za pritezanje (11) načinjena u dva dijela, s osnovnim dijelom, koji ima klizni profil (12) i povezan je s vrpcom za pritezanje (13), i s polugom i dijelom za hvatanje, povezanim s osnovnim dijelom uklonjivom vezom.
The compounds according to any one of claims 5 to 7, or tautomers, racemates, enantiomers, diastereoisomers, and mixtures thereof, and pharmaceutically acceptable salts thereof, wherein n is 2. 
Spojevi sukladno patentnom zahtjevu 1 do 4, ili tautomeri, racemati, enantiomeri, dijastereomeri, i njihove smjese, i njihove farmaceutski prihvatljive soli, pri čemu n je 2.
at least one pulley (35) assembled on said trolley of said recovery and expulsion system of said kite (2); 
- < najmanje jedan koloturnik (35) montiran na spomenuta kolica spomenutog sustava za vraćanje 1 izbacivanje zmaja (2)
Package according to claim 4 or 5, wherein the means (14) for dividing the modules is a perforation in the wrapping (3) which is arranged in a circumferential direction around the wrapping (3) of the modules (6; 6a, 6b, 6c). 
Paket u skladu s patentnim zahtjevom 3, naznačen time, da je sredstvo za (14) dijeljenje modula perforacija u omotu (3) koja je postavljena po obodu oko omota (3) modula (6; 6a, 6b, 66).
The process of claim 6 wherein the isolated fibrids are dried. 
Postupak u skladu s patentnim zahtjevom 6, pri čemu se izolirani fibridi suše.
The pharmaceutical composition of any one of claims 1(b) or 2 wherein the crosslinked amine polymer has an equilibrium swelling ratio in deionized water of about 4 or less, about 3 or less, or about 2 or less. 
Farmaceutski pripravak za upotrebu prema zahtjevu 1, naznačen time da umreženi aminski polimer ima ravnotežni odnos bubrenja u deioniziranoj vodi od 4 ili manji, ili 3 ili manji, ili 2 ili manji, ili 1,5 ili manji, ili 1 ili manji.
In one embodiment, the anti-KIR antibody and anti-PD-1 antibody are administered at the following doses: 
Antitijela za primjenu iz patentnog zahtjeva 1, gdje anti-KIR antitijelo i anti-PD-1 antitijelo su za administraciju u sljedećim dozama:
determining a driver profile from the events; and characterising the driving behaviour of the driver on the basis of the driver profile. 
utvrđivanje (4) profila vozača (24) iz odabranog događaja; i određivanje (9) ponašanja u vožnji vozača temeljem vozačevog profila.
R4a-Y (X) where R4a represents an R4 group as defined in claim 1 optionally in protected form, and 
a-Y (X) gdje R4a predstavlja skupinu R4 kao što je definirano u patentnom zahtjevu 1 koja može biti u zaštićenom obliku, te Y je izlazna skupina kao što je Cl, Br, I, OSO2CH3, OSO2CF3 ili O-Tosil.
13 through 17 . For example, as shown in FIG. 13, paclitaxel of Formula 1 (where R1=R2=Ph; R7=CH3 in generalized formula A of Scheme 1) is first protected at the 2′-hydroxyl with a hydroxyl protecting group such as tert-butyidimethylsilyl (TBDMS). 
Takav postupak je prikazan kao primjer na slikama 13 do 17. Na primjer, kao što je prikazano na slici 13, paklitaksel formule 1 (gdje Ri=R>=Ph; R;=CH; u općoj formuli A iz sheme 1) je najprije zaštićen na 2'-hidroksilu s hidroksil zaštitnom skupinom kao što je tert-butildimetilsilil (TBDMS).
A transgenic host according to claim 12, wherein the light chain encoding nucleic acid molecule is provided with a means that allows expression of the light chain encoding nucleic acid molecule predominantly during a certain stage of the development of B cells. 
Transgeni murinski sisavac prema zahtjevu 5, naznačen time, da se pribavlja molekula nukleinske kiseline koja kodira slabi lanac, zajedno sa sredstvom koje dopušta ekspresiju molekule nukleinske kiseline koja kodira slabi lanac, većinom za vrijeme određene faze u razvoju B-stanica.
The crude product was purified by flash chromatography on silica using gradient elution (ethyl acetate/heptane). 
Sirovi produkt se pročisti sa brzom kromatografijom na silika gelu uz korištenje gradijenta ispiranja (etil acetat/heptan).
conditioning equipment 69 
oprema za kondicioniranje 69
A process for the manufacture of a cosmetic composition comprising incorporating vesicles produced by the method of claim 1 into an acceptable excipient, wherein the cosmetic composition is for inhibiting senescence of the skin. 
Upotreba čestica iz bilo kojeg od patentnih zahtjeva 1-6, u proizvodnji kozmetičkog proizvoda, preporučljivo da je kozmetički proizvod proizvod za sprječavanje propadanja kao u slučaju starosti i starenja kože.
The use of opioid antagonists according to claim 1 wherein the opioid antagonist such as naltrexone, naloxone or nalmefene is administred to the patient topically in the form of creams, ointments, gels, eye drops, lotions, suppositories and enemas. 
Uporaba opioidnih antagonista prema zahtjevu 1 naznačena time da se opioidni antagonist kao što je naltrekson, nalokson ili nalmefen daje pacijentu topikalno u obliku krema, masti, gelova, kapi za oči, losiona, čepića 1 klistira.